{"analyses":[{"ciLowerLimit":"5.9567","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"37.1225","groupDescription":"Female gender as patient-level predictor for cancer-related mortality","groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","paramType":"Odds Ratio (OR)","paramValue":"14.8703","statisticalMethod":"Regression, Logistic","testedNonInferiority":false},{"ciLowerLimit":"5.9567","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"37.1225","groupDescription":"Poor performance (ECOG \\>=2) during study as patient-level predictor","groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","paramType":"Odds Ratio (OR)","paramValue":"14.8703","statisticalMethod":"Regression, Logistic","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1385"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1385"}],"units":"Participants"}],"description":"Objective 10: To model patient- and center-level variables between patients who died vs. survived during the course of primary or secondary prophylaxis with EP2006 in all patients and those with break-through FN episodes.\n\nTable presents patient level predictors for cancer-related mortality: female gender, poor performance (ECOG \\>=2) during study.\n\nECOG score is a severity scale from 0 to 5 (highest) to grade toxicity and is defined as follows: 0=none, 1=mild, 2=moderate, 3=severe, 4=life-threatening, 5=lethal. ECOG is described in more detail by Oken et al, Am J Clin Oncol (CCT) 5:649-655, 1982.","groups":[{"description":"Cancer patients treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN","id":"OG000","title":"EP2006"}],"paramType":"NUMBER","populationDescription":"Evaluable sample with data","reportingStatus":"POSTED","timeFrame":"All cycles. Patients were evaluated at the enrollment cycle and then re-evaluated at each cycle for a maximum total of 6 cycles; however, the scheduling of these evaluations was left to the discretion of the physician, mean duration of study for 105 days","title":"Patient-level Predictor for Cancer-related Mortality","type":"SECONDARY","unitOfMeasure":"participants"}